Management of patients at very high risk of osteoporotic fractures through sequential treatments

Accepted/In Press date: 18 February 2022

e-pub ahead of print date: 24 March 2022

Published date: April 2022

Additional Information: Funding Information: The ESCEO Working Group was funded by the ESCEO. The ESCEO receives unrestricted educational grants to support its educational and scientific activities from non-governmental organisations, not-for-profit organisations, non-commercial or corporate partners. The choice of topics, participants, content and agenda of the Working Groups as well as the writing, editing, submission and reviewing of the manuscript are the sole responsibility of the ESCEO, without any influence from third parties. Funding Information: E.M.C. reports lecture fees and travel support from Eli Lilly, Pfizer and UCB, outside the submitted work. N.A.D. reports no conflict of interest. E.B. reports lecture fees from Amgen, outside the submitted work. M.L.B. reports honoraria from Amgen, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB, grants or speaker fees from Abiogen, Alexion, Amgen, Bruno Farmaceutici, Echolight, Eli Lilly, Kyowa Kirin, SPA, Theramex, UCB and consulting fees from Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB, outside the submitted work. E.C. EC is consultant for DiaSorin, IDS, Fujirebio and Nittobo. P.Hadji. reports personal fees, consultancy, lecture fees and honoraria from AMGEN, Eli Lilly, Fresenius, Gedeon Richter, Hexal, MSD, Novartis, Roche, Stada, Theramex, UCB, outside the submitted work. P. Halbout reports no conflict of interest. N.C.H. reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, UCB, Kyowa Kirin, Servier, Shire, Consilient Healthcare and Internis Pharma, outside the submitted work. MKJ reports personal fees from Amgen, UCB and Besin Healthcare institutional grant support from Amgen and UCB outside of the submitted work. M.H. has received research grants through institution from Amgen, Radius Health, BD, ViiV Healthcare, lecture fees from Teva and Mylan, and consulting fees from UCB outside the submitted work. M.K.J. reports no conflict of interest. J.A.K.: Nothing to declare. JAK is the architect of FRAX® but has no financial interest. J-M.K. reports no conflict of interest in relation to the submitted work. O.L. reports no conflict of interest. R.M. reports no conflict of interest. A.D-P. reports lecture fees from Eli Lilly, Amgen and Gedeon Richter outside the submitted work. R.P.R.: Nothing to declare for the submitted work. M.R. reports no conflict of interest in relation to the submitted work. T.T. has received consultancy/speaker’s fees from Amgen, Arrow, Biogen, Chugai, Expanscience, Grunenthal, Jansen, LCA, Lilly, MSD, Nordic, Novartis, Pfizer, Sanofi, Thuasne, Theramex, TEVA et UCB and financial support or fees for research activities from: Bone Therapeutics, Chugai, UCB. F.T. reports personal fees, consultancy, lecture fees and honoraria from AMGEN, Fresenius, Gedeon-Richter, Hexal, HOLOGIC, Kyowa-Kirin, Stadapharm, Theramex, UCB, outside the submitted work. M.V. reports no conflict of interest in relation to the submitted work. J.Y.R. has received fees for lectures or advisory boards from IBSA-Genevrier, Mylan, Radius Health, Pierre Fabre, Faes Pharma, Rejuvinate Biomed, Teva, Theramex, Pfizer, Mithra Pharmaceuticals, CNIEL, Dairy Research Council, Nutricia, Danone and Agnovos, and industry grants (all through institution) from IBSA-Genevrier, Mylan, CNIEL, Radius Health and TRB, outside the submitted work. R.R. has received fees for lectures or advisory boards from Abiogen, Amgen, Danone, Echolight, European Milk Forum, Mithra, Nestlé, ObsEva, Pfizer Consumer Health, Radius Health, Rejunevate and Theramex. C.C. reports personal fees from ABBH, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier and Takeda, outside the submitted work. Publisher Copyright: © 2022, The Author(s). © 2022. The Author(s).

Keywords: Anabolic, Antiresorptive, Epidemiology, Fracture, Imminent, Osteoporosis

Local EPrints ID: 456252

URI: http://eprints.soton.ac.uk/id/eprint/456252

DOI: doi:10.1007/s40520-022-02100-4

ISSN: 1594-0667

PURE UUID: 92de8e72-9f74-4a76-9c4f-f45dcee98d19

ORCID for Elizabeth M. Curtis: orcid.org/0000-0002-5147-0550

ORCID for Nicholas C. Harvey: orcid.org/0000-0002-8194-2512

ORCID for Cyrus Cooper: orcid.org/0000-0003-3510-0709

Date deposited: 26 Apr 2022 23:30

Last modified: 18 Mar 2024 03:38